6318-64-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Methoxy-5-acetylaniline is used as an intermediate for the production of various pharmaceuticals, including antihistamines and anti-inflammatory drugs, due to its chemical properties and reactivity.
Used in Dye Industry:
2-Methoxy-5-acetylaniline is used as an intermediate in the synthesis of dyes, contributing to the development of colorants for various applications.
Used in Chemical Research:
2-Methoxy-5-acetylaniline serves as a valuable compound in chemical research for the development of new chemical entities and understanding its reactivity and properties in different chemical reactions.

InChI:InChI=1/C9H11NO2/c1-6(11)7-3-4-9(12-2)8(10)5-7/h3-5H,10H2,1-2H3

Upstream product

• 6277-38-9 1-(4-methoxy-3-nitrophenyl)ethanone 
• 100-06-1 1-(4-methoxyphenyl)ethanone 

Downstream Products

• 79324-77-9 1‐(3‐iodo‐4‐methoxyphenyl)ethan‐1‐one 
• 113016-89-0 5‐acetyl‐2‐methoxybenzonitrile 
• 74896-31-4 acetic acid-(5-acetyl-2-methoxy-anilide) 
• 109840-53-1 morpholino-acetic acid-(5-acetyl-2-methoxy-anilide) 
• 85276-46-6 5-acetyl-2-methoxybenzenesulfonamide 
• 85276-41-1 5-acetyl-2-methoxybenzenesulfonyl chloride 
• 861552-83-2 1,3-bis-(5-acetyl-2-methoxy-phenyl)-triazene 
• 85276-53-5 5-acetyl-2-methoxy-N-methylbenzenesulfonamide 
• 70959-70-5 5-(2-Bromo-acetyl)-2-methoxy-benzenesulfonamide 
• 85276-60-4 5-(2-Bromo-acetyl)-2-methoxy-N-methyl-benzenesulfonamide 
• 345649-09-4 2-Hydroxy-5-[1-hydroxy-2-(1-methyl-2-phenoxy-ethylamino)-ethyl]-benzenesulfonamide 
• 345948-60-9 5-{2-[Benzyl-(1-methyl-2-phenoxy-ethyl)-amino]-1-hydroxy-ethyl}-2-hydroxy-benzenesulfonamide 
• 344754-71-8 5-{2-[Benzyl-(1-methyl-3-phenyl-propyl)-amino]-1-hydroxy-ethyl}-2-methoxy-N-methyl-benzenesulfonamide 
• 345948-61-0 5-{2-[Benzyl-(1-methyl-2-phenoxy-ethyl)-amino]-acetyl}-2-hydroxy-benzenesulfonamide 

Relevant academic research and scientific papers

Identification, structure modification, and characterization of potential small-molecule SGK3 inhibitors with novel scaffolds

The serum and glucocorticoid-regulated kinase (SGK) family has been implicated in the regulation of many cellular processes downstream of the PI3K pathway. It plays a crucial role in PI3K-mediated tumorigenesis, making it a potential therapeutic target for cancer. SGK family consists of three isoforms (SGK1, SGK2, and SGK3), which have high sequence homology in the kinase domain and similar substrate specificity with the AKT family. In order to identify novel compounds capable of inhibiting SGK3 activity, a high-throughput screening campaign against 50,400 small molecules was conducted using a fluorescence-based kinase assay that has a Z' factor above 0.5. It identified 15 hits (including nitrogen-containing aromatic, flavone, hydrazone, and naphthalene derivatives) with IC50 values in the low micromolar to sub-micromolar range. Four compounds with a similar scaffold (i.e., a hydrazone core) were selected for structural modification and 18 derivatives were synthesized. Molecular modeling was then used to investigate the structure-activity relationship (SAR) and potential protein–ligand interactions. As a result, a series of SGK inhibitors that are active against both SGK1 and SGK3 were developed and important functional groups that control their inhibitory activity identified.

Design, synthesis and biological evaluation of paralleled Aza resveratrol-chalcone compounds as potential anti-inflammatory agents for the treatment of acute lung injury

Acute lung injury (ALI) is a major cause of acute respiratory failure in critically-ill patients. It has been reported that both resveratrol and chalcone derivatives could ameliorate lung injury induced by inflammation. A series of paralleled Aza resveratrol-chalcone compounds (5a-5m, 6a-6i) were designed, synthesized and screened for anti-inflammatory activity. A majority showed potent inhibition on the IL-6 and TNF-α expression-stimulated by LPS in macrophages, of which compound 6b is the most potent analog by inhibition of LPS-induced IL-6 release in a dose-dependent manner. Moreover, 6b exhibited protection against LPS-induced acute lung injury in vivo. These results offer further insight into the use of Aza resveratrol-chalcone compounds for the treatment of inflammatory diseases, and the use of compound 6b as a lead compound for the development of anti-ALI agents.

Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization

The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by crystal structure analysis, we reversed the sulfonamide group and identified a new binding mode. A structure-activity relationship study on this new series led to several potent BRD4 inhibitors with IC50 of about 0.05-0.1 μM in FP binding assay and GI50 of 0.1-0.3 μM in cell based assays. To complete the lead-like assessment of this series, we further checked its effects on BRD4 downstream protein c-Myc, investigated its selectivity among five different bromodomain proteins, as well as the metabolic stability test, and reinforced the utility of 2-thiazolidinone scaffold as BET bromodomain inhibitors in novel anticancer drug development.

PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyridazinone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1 represents H or C1-6 alkyl, each of R2 and R3 represents H, X, C1-6 alkoxy, Z represents O or S, and A represents AA or BB, wherein AA represents: and BB represents: wherein R4 represents H or C1-6 alkyl, and each of R5 and R6 represents C1-6 alkyl.

N-acyl anilines, useful for gastro-enterological disorders

This invention relates to novel N-acyl anilines, to a process for their preparation and to pharmaceutical compositions containing them. The N-acyl anilines are obtained by condensing a substituted aniline with an aminolower alkyl carboxylic acid or a functional derivative thereof. The compounds of the invention have therapeutic utility namely in the gastro-enterologic field.